February 25, 2020 | English | عربي
   Add to Twitter
 
Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease
- New data from the VISIBLE 2 trial presented at the 15th Congress of the European Crohn’s and Colitis Organisation (ECCO)